Calciscon Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$2.68M
- Investors
-
4
Calciscon General Information
Description
Developer of calcification propensity diagnostics equipment intended to improve the cardiovascular risk management of kidney patients. The company's product measures crystal formation time, magnesium in serum, and fetuin-A in serum, as well as offers a measurement service for testing calcification propensity in blood, urine, or other sample types, enabling patients to identify those at elevated risk of developing pathologic calcification.
Contact Information
Website
www.calciscon.comCorporate Office
- Aarbergstrasse 46
- 2503 Biel/Bienne
- Switzerland
Corporate Office
- Aarbergstrasse 46
- 2503 Biel/Bienne
- Switzerland
Calciscon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | 14-Apr-2021 | $2.68M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 23-Jul-2020 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Sep-2017 | Completed | Startup | |||
| 6. Debt - General | 01-Jan-2016 | Completed | Startup | |||
| 5. Seed Round | 23-Mar-2015 | Completed | Startup | |||
| 4. Grant | 18-Jun-2014 | Completed | Startup | |||
| 3. Seed Round | 26-Mar-2014 | Completed | Startup | |||
| 2. Grant | 03-Dec-2013 | $164K | Completed | Startup | ||
| 1. Grant | 23-Apr-2013 | $21.3K | Completed | Startup |
Calciscon Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Series Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Calciscon Patents
Calciscon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3002590-A1 | A method for determining the propensity for calcification | Active | 07-Nov-2011 | ||
| EP-3002590-B1 | A method for determining the propensity for calcification | Active | 07-Nov-2011 |
Calciscon Signals
Calciscon Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Yellowstone Holding | Venture Capital | Minority | ||
| W. A. de Vigier Foundation | Limited Partner | |||
| Robert and Ruth Heuberger Foundation | Limited Partner | |||
| Venture Kick | Accelerator/Incubator | Minority |
Calciscon FAQs
-
When was Calciscon founded?
Calciscon was founded in 2013.
-
Where is Calciscon headquartered?
Calciscon is headquartered in Biel/Bienne, Switzerland.
-
What is the size of Calciscon?
Calciscon has 4 total employees.
-
What industry is Calciscon in?
Calciscon’s primary industry is Diagnostic Equipment.
-
Is Calciscon a private or public company?
Calciscon is a Private company.
-
What is Calciscon’s current revenue?
The current revenue for Calciscon is .
-
How much funding has Calciscon raised over time?
Calciscon has raised $5.02M.
-
Who are Calciscon’s investors?
Yellowstone Holding, W. A. de Vigier Foundation, Robert and Ruth Heuberger Foundation, and Venture Kick have invested in Calciscon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process